Loading stock data…
CRL
$165.78-1.19 (-0.71%)
Market ClosedLast close May 1
Charles River Laboratories International, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Charles River Laboratories International, Inc. in the Healthcare sector is trading at $165.78. The stock is currently 28% below its 52-week high of $228.88, remaining 5.8% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why CRL maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$165.78
Potential Upside
5%
Whystock Fair Value$174.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target$199.33+20.2%
Range$135.00 – $265.00
Fundamentals
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.19%
Volume
Today's trading volume
464,893
Recent News
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Charles River Laboratories (CRL) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
1 S&P 500 Stock to Own for Decades and 2 We Find Risky
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Assessing Charles River Laboratories (CRL) Valuation After Progress In Virtual Control Group Toxicology Studies
Charles River Laboratories International (CRL) recently reported that its virtual control groups in toxicology studies matched traditional control groups on key outcomes, supporting efforts to reduce animal use while keeping study quality intact. See our latest analysis for Charles River Laboratories International. At a share price of US$183.10, the stock has a 1 month share price return of 19.21%, but that sits against a 90 day share price decline of 19.26% and a 5 year total shareholder...
What You Need to Know Ahead of Charles River Laboratories' Earnings Release
Charles River Laboratories will release its first-quarter earnings next month, and analysts anticipate a double-digit profit dip.